preload preload preload preload preload preload preload preload preload

Molecular Response logo

Primary tumor cells

Molecular Response is the only service company in the world able to perform ex vivo drug treatments on hundreds or thousands of primary tumor cells for a single study.

CELL TREATMENT

We provide the most well-powered ex vivo tumor cell studies by leveraging the proprietary Molecular Response Tumor Bank, comprising more than 140,000 cryopreserved single cell suspensions, covering 76 clinical cancer diagnoses.

STUDIES ON TARGET

By leveraging the Tumor Bank, we are able to select tumor cells featuring molecular characteristics of interest and test those cases in drug treatment studies. Our comprehensive molecular testing capabilities allow us to identify tumor of interest based on:

  • Protein/antigens expression
  • Gene expression
  • Copy number variation
  • Genetic mutation

 

This enables well-defined and well-powered studies for tumors that are positive for your therapeutic target or molecular marker.

RESPONSIVE POPULATIONS

The breadth of the tumor bank enables studies that capture typical biological variability seen across a population, which serves two purposes:
1) Added confidence of treatment efficacy within a population
2) Identification of responsive subpopulations within or across indications

The ability to identify responsive and non-responsive populations is the first step toward identifying molecular markers related to response — either predictive or pharmacodynamics.

An example study leveraging the Molecular Response Tumor Bank examined 20 primary colorectal tumor cells for proliferation following treatment with HDAC inihibitor. The study identified a spectrum of response, featuring a gene expression marker that highly correlated to drug sensitivity (Figure 1).

MEASURING RESPONSE

In order to measure comprehensive drug response, we look at several endpoints, including:
• proliferation • apoptosis/necrosis • motility • invasion • signaling • PD markers

DATA REPORTING

We routinely report back growth inhibition curves and GI50 values across a population of primary tumor cases for a given drug or drug combination treatment. To get the best understanding of drug sensitivity, our data analysis group; however, incorporates multiple cellular endpoints, as well as know molecular features for each cell line.

Figure 1. A) 20 colorectal primary tumor cases demonstrate differential response to HDAC inhibitor. B) 7 most resistant vs. 7 most sensitive cases demonstrate differential gene expression for specific marker.